AffyImmune Therapeutics
PrivateLast Round
Series A
Oct 7, 2021
Total Funding Raised
$38.55M
Company Overview
AffyImmune Therapeutics is a biotechnology company that develops affinity-tuned CAR T cell therapies for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AffyImmune Therapeutics Comparables
Compare AffyImmune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Innovative Cellular Therapeutics | 87% | |
| Bio4t2 | 87% | |
| Leucid Bio | 85% | |
AffyImmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 7, 2021 | ||||
| Grant | May 25, 2021 | ||||
| Series A | Nov 28, 2018 |
AffyImmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Cornell University Office of University Investments | Series A |
| ORI Capital | Series A |
AffyImmune Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AffyImmune Therapeutics's valuation, stock price, and market status.